Israel’s IceCure Medical (see here previously) presented the results of its three clinical studies using ProSense to treat breast cancer. Of the 389 patients treated, The ipsilateral tumor recurrence rate was 0.26%, resulting in a 99.74% recurrence-free rate.

https://www.prnewswire.com/il/news-releases/independent-study-results-in-japan-demonstrate-zero-0-breast-cancer-local-recurrence-5-years-following-treatment-with-icecures-prosense-adding-to-continued-positive-data-published-globally-302137926.html